Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Common Equity (2023 - 2025)

Kura Oncology (KURA) has disclosed Common Equity for 3 consecutive years, with $174.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 57.9% to $174.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $174.1 million, a 57.9% decrease, with the full-year FY2025 number at $174.1 million, down 57.9% from a year prior.
  • Common Equity was $174.1 million for Q4 2025 at Kura Oncology, down from $242.5 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $505.1 million in Q1 2024 to a low of $174.1 million in Q4 2025.
  • A 3-year average of $381.4 million and a median of $405.5 million in 2023 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: grew 27.81% in 2024, then crashed 57.9% in 2025.
  • Kura Oncology's Common Equity stood at $397.3 million in 2023, then grew by 4.12% to $413.6 million in 2024, then plummeted by 57.9% to $174.1 million in 2025.
  • Per Business Quant, the three most recent readings for KURA's Common Equity are $174.1 million (Q4 2025), $242.5 million (Q3 2025), and $305.5 million (Q2 2025).